Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone High-Dose - 2 doses Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

NCT01135329
View directory record Official record
Conditions
Lymphoma, Leukemia, Myelodysplastic Syndrome
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo, HD quadrivalent influenza vaccine
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A/H5N1/LT Dose Ranging Study

NCT00908687
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, LT Adjuvant Patch
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Anaheim, California • Vallejo, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

NCT06821061
View directory record Official record
Conditions
Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions
Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine
Biological · Combination Product
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
31
States / cities
Anaheim, California • Lake Forest, California • Riverside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5N1 (Clade 2) Vaccination of Adults and Elderly

NCT00680069
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 99 Years
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
8
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

NCT02566265
View directory record Official record
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

NCT01776554
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
6 Months to 17 Years
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Newton, Kansas • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

NCT02860039
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions
Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
3 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 7, 2026, 8:45 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 7, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of H1N1 Vaccine

NCT01177202
View directory record Official record
Conditions
H1N1 Flu
Interventions
HAC1 Vaccine
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

NCT01691339
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

NCT00519389
View directory record Official record
Conditions
Pandemic Influenza
Interventions
H5N1 VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 7, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 7, 2026, 8:45 AM EDT